Transfusion-Associated Circulatory Overload Best Eliminated With Lasix

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot double-blinded placebo-controlled randomized controlled trial (RCT) to evaluate the feasibility of conducting a multicenter, randomized, placebo-controlled trial to assess the efficacy of pre-transfusion furosemide in preventing transfusion-associated circulatory overload (TACO) in hemodynamically stable inpatients aged 65 years or older receiving a single unit red blood cell transfusion. Patients will be randomly allocated to receive either furosemide (20mg intravenous) or placebo (saline) within 60 minutes of starting a red blood cell (RBC) transfusion. Randomization will be stratified by centre and renal dysfunction (creatinine clearance ≥ 60 mL/min or \< 60 mL/min). This is a blinded trial: patients, care-providers (physicians and nurses), data collectors, outcome adjudicators, and data analysts will not be aware of group allocation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME

NCT06766032

Cardiac Surgery Under Extra Corporeal Circulation Cardiac Surgery Requiring Cardiopulmonary Bypass

COMPLETED

Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy

NCT02966236

Nephrolithiasis Staghorn Calculus

UNKNOWN PHASE4

INR-Triggered Transfusion In GI Bleeders From ER

NCT01461889

Respiratory Distress Syndrome, Adult Gastrointestinal Hemorrhage Liver Diseases +1 more

TERMINATED PHASE3

Pre-hospital Administration of Fibrinogen in Trauma-Induced Coagulopathy

NCT06582420

Trauma Induced Coagulopathy

NOT_YET_RECRUITING NA

Predicting Lung Injury From Transfusion in Patients With Liver Disease

NCT01756690

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators proposed this pilot study to assist us in determining the feasibility of conducting a definitive multicenter randomized trial across Canada.

Rationale:

The rationale for this study includes: (1) TACO is the leading cause of morbidity and mortality due to transfusion; (2) risk factors for TACO include older age, renal dysfunction and positive fluid balance; (3) furosemide is a diuretic commonly prescribed for fluid overload; (4) furosemide can decrease pulmonary artery pressures; and (5) clinical uncertainty as to the effect of furosemide in preventing TACO. The investigators will enroll 80 patients in this pilot study at two centers.

Hypothesis:

The investigators hypothesize that 80 patients can be enrolled in the trial within a 2-month period

Justification:

If pre-transfusion that furosemide decreases the rate of TACO with red blood cell transfusion, clinical practice worldwide would change. Over 800,000 patients in Canada receive a blood transfusion annually and many are at high risk for TACO and may benefit from this simple, low-cost intervention. This intervention could easily be generalizable worldwide. There are practical challenges related to patient recruitment, adherence to trial protocol and data collection, all of which the TACO-BEL Pilot Trial will seek to measure.

Objectives:

The primary outcome of this trial is to determine the feasibility of performing a large multi-centre, randomized, placebo-controlled trial with concealed allocation and blinded outcome assessment, adequately powered to determine a clinically significant effect of pre-transfusion furosemide on the incidence of transfusion-associated circulatory overload.

Primary outcome measure is the number of patients enrolled within a two-month period

Secondary feasibility outcome measures include:

1. Proportion of patients screened meeting eligibility criteria
2. Proportion of eligible patients consenting to participate
3. Proportion of consenting patients receiving the allocated treatment
4. Proportion of treated patients completing follow-up assessment
5. Proportion of patients in which blinding was maintained throughout study

Research Method:

Patients meeting inclusion criteria will be identified by reviewing transfusion orders received by the blood transfusion laboratory or by referral from ordering physicians; these patients will then be approached by study personnel to obtain pre-transfusion informed consent. Randomization will be performed by pharmacy at the time of drug preparation. The randomization code will be generated in random blocks of 4 to 6, stratified by center, and renal function at time of randomization (creatinine clearance \< 60 and ≥ 60 mL/min) using a computer based randomization program.

Intervention:

Patients will be administered a bolus dose of 20mg furosemide (20mg/2mL) intravenously within 60 minutes prior to the start of the red blood cell transfusion. Patients randomized to placebo will be administered an equal volume of normal saline intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transfusion-associated Circulatory Overload

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Furosemide

Diuretic

Group Type EXPERIMENTAL

Furosemide

Intervention Type DRUG

A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.

Placebo

Normal saline

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type DRUG

A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Furosemide

A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.

Intervention Type DRUG

Normal Saline

A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lasix 0.9% Sodium Chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years.
* Receiving a single unit red blood cell transfusion

Exclusion Criteria

* Active bleeding (active visible bleeding, required 2 or more RBC units in the preceding 24 hours, drop in Hb \> 20 g/L in the preceding 24 hours);
* Hemodynamically unstable (systolic blood pressure \< 90 mmHg or on inotropes);
* Anticipated major surgical procedure within 24 hours of enrolment;
* Presence of hyponatremia (Na \< 130 mmol/L);
* Presence of hypokalemia (K \< 3.5 mmol/L);
* Dialysis or creatinine clearance \< 30 mL/min;
* Order for platelet or plasma transfusion at same time;
* Allergy to furosemide;
* Risk of withholding furosemide felt by attending physician to place patient at excessive risk of harm;
* Previously enrolled in the study;
* Plan for discharge on the day of randomization;
* Unable to provide informed consent.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No